跳至主要内容
临床试验/NCT00913159
NCT00913159终止不适用

A Randomized Controlled Trial Comparing Efficacy of HM3 vs F2 Lithotripters for Stone Fragmentation

Washington University School of Medicine1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2009年11月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
5
试验地点
1
主要终点
Stone free rate, complications and need for ancillary procedures

研究概览

简要总结

The older lithotripter, HM3, has over 90% stone-free rate in most studies. However, it's less transportable than the new model, F2. There are no prospective trials performed to make a valid comparison between these 2 lithotripters in terms of efficacy of stone fragmentation and clinical outcomes.

详细描述

Shock wave kidney stone treatment was introduced in the 1980's. It is the least invasive method to treat kidney stone disease. The unmodified Dornier HM3 has over 90% stone free rate in most studies. The MH3 requires immersion in a full bath, necessitating dedicated operative space. The new generation model F2 uses water cushion as a coupling medium and is easily transported. The generators used in both machines are also different. The newer model has the advantage of being more convenient due to portability and ease of use of the coupling medium, but there have been no prospective studies to compare these 2 machines in terms of efficacy of stone fragmentation and clinical outcomes. We seek to compare the HM3 with the F2 models in terms of stone free rates, complications and clinical outcomes to determine which machine is the most effective and will limit the need for additional stone procedures.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients diagnosed with urolithiasis and choose to have ESWL treatment
  • •Age 18-90 years old
  • •Able to understand the informed consent

排除标准

  • •Cognitively impaired

研究组 & 干预措施

Using HM3 lithotripter

Active Comparator

This is an older generation lithotripter

干预措施: Extracorporeal Shock Wave Lithotripsy (ESWL) (Procedure)

F2 lithotripter

Active Comparator

This is a newer generation lithotripter

干预措施: Extracorporeal Shock Wave Lithotripsy (ESWL) (Procedure)

结局指标

主要结局

Stone free rate, complications and need for ancillary procedures

时间窗: 3-5 years

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

已完成
3 期
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate CancerProstate AdenocarcinomaStage I Prostate Adenocarcinoma AJCC v7Stage II Prostate Adenocarcinoma AJCC v7Stage III Prostate Adenocarcinoma AJCC v7
NCT03274687NRG Oncology296
进行中(未招募)
1 期
Estudio Fase III, randomizado, que compara el tratamiento estándar de primera línea docetaxel/prednisona en combinación con custirsen (OGX-011) en varones con cáncer de próstata metastásico hormonoresistente// A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer - SYNERGYCÁNCER DE PROSTATA METASTÁSICO HORMONORESISTENTE// metastatic castrate resistant prostate cancerMedDRA version: 12.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticMedDRA version: 12.1Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancer
EUCTR2010-021011-16-ESTeva Pharmaceutical Industries, Ltd1,022
已完成
3 期
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study OneNervous System DiseasesMultiple sclerosis
ISRCTN21534255Genzyme Corporation (USA)581
已完成
3 期
Hypofractionated Radiation Therapy in Patients With Breast CancerBreast Cancer
NCT04075058Post Graduate Institute of Medical Education and Research, Chandigarh1,070
已完成
3 期
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)Tubular Breast Cancer Stage IIMucinous Breast Cancer Stage IIBreast Cancer Female NOSInvasive Ductal Breast CancerInflammatory Breast CancerHER2 Positive Breast CancerTubular Breast Cancer Stage III
NCT02125344German Breast Group961